Radiotheranostics: A roadmap for future development Review
| Authors: | Herrmann, K.; Schwaiger, M.; Lewis, J. S.; Solomon, S. B.; McNeil, B. J.; Baumann, M.; Gambhir, S. S.; Hricak, H.; Weissleder, R. |
| Review Title: | Radiotheranostics: A roadmap for future development |
| Abstract: | Radiotheranostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid development over the past decade. Although some formulations are already approved for human use, more radiopharmaceuticals will enter clinical practice in the next 5 years, potentially introducing new therapeutic choices for patients. Despite these advances, several challenges remain, including logistics, supply chain, regulatory issues, and education and training. By highlighting active developments in the field, this Review aims to alert practitioners to the value of radiotheranostics and to outline a roadmap for future development. Multidisciplinary approaches in clinical trial design and therapeutic administration will become essential to the continued progress of this evolving therapeutic approach. © 2020 Elsevier Ltd |
| Keywords: | unclassified drug; review; cancer combination chemotherapy; liver cell carcinoma; bone metastasis; capecitabine; ibritumomab tiuxetan; colorectal cancer; paraganglioma; unindexed drug; quality of life; multiple myeloma; breast cancer; bone pain; neuroendocrine tumor; prostate cancer; liver metastasis; b cell lymphoma; nonhodgkin lymphoma; neuroblastoma; diagnostic value; head and neck cancer; lymphoma; radiopharmaceutical agent; (3 iodobenzyl)guanidine; pancreas adenocarcinoma; stomach cancer; staff training; thyroid cancer; large cell lymphoma; (3 iodobenzyl)guanidine i 131; glass; pheochromocytoma; general practitioner; tositumomab i 131; patient attitude; follicular lymphoma; radioactive microsphere; resin; olaparib; tositumomab; small cell lung cancer; drug indication; castration resistant prostate cancer; iodine; futurology; central nervous system metastasis; study design; small cell sarcoma; bone marrow tumor; yttrium 90; prostate metastasis; diffuse large b cell lymphoma; lexidronam samarium sm 153; strontium 89; interdisciplinary research; strontium chloride sr 89; lead 212; nivolumab; radium chloride ra 223; human; priority journal; pembrolizumab; oxodotreotide lu 177; theranostic nanomedicine; indolent nonhodgkin lymphoma; omburtamab; 3 bp 227; adacap; apamistamab i 131; bismuth 231; curium; fibroblast activated protein inhibitor; lilotomab satetraxetan lutetium lu 177; lutetium 3 bp 227 lu 177; lutetium pentixather lu 177; radiotheranostic agent; satoreotide tetraxetan; tetulomab tetraxetan lutetium lu 177; vipivotide tetraxetan; yttrium pentixather y 90; transformed lymphoma |
| Journal Title: | Lancet Oncology |
| Volume: | 21 |
| Issue: | 3 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2020-03-01 |
| Start Page: | e146 |
| End Page: | e156 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(19)30821-6 |
| PUBMED: | 32135118 |
| PROVIDER: | scopus |
| PMCID: | PMC7367151 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 April 2020 -- Source: Scopus |
